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Abstract:  70 years have passed since the first isolation of the naphthodianthrones 
hypericin and pseudohypericin from Hypericum perforatum L. Today, they continue to be 
one of the most promising group of polyphenols, as they fascinate with their physical, 
chemical and important biological properties which derive from their unique chemical 
structure. Hypericins and their derivatives have been extensively studied mainly for their 
antitumor, antiviral and antidepressant properties. Notably, hypericin is one of the most 
potent naturally occurring photodynamic agents. It is able to generate the superoxide anion 
and a high quantum yield of singlet oxygen that are considered to be primarily responsible 
for its biological effects. The prooxidant photodynamic properties of hypericin have been 
exploited for the photodynamic therapy of cancer (PDT), as hypericin, in combination with 
light, very effectively induces apoptosis and/or necrosis of cancer cells. The mechanism by 
which these activities are expressed continues to be a main topic of discussion, but 
according to scientific data, different modes of action (generation of ROS & singlet oxygen 
species, antiangiogenesis, immune responces) and multiple molecular pathways 
(intrinsic/extrinsic apoptotic pathway, ERK inhibition) possibly interrelating are 
implicated. The aim of this review is to analyse the most recent advances (from 2005 and 
thereof) in the chemistry and biological activities (in  vitro and in  vivo) of the pure 
naphthodianthrones, hypericin and pseudohypericin from H. perforatum. Extracts from H. 
perforatum were not considered, nor pharmakokinetic or clinical data. Computerised 
literature searches were performed using the Medline (PubMed), ChemSciFinder and 
Scirus Library databases. No language restrictions were imposed. 
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1. Introduction 
1.1. Distribution, Plant Sources 
Hypericin (1) and pseudohypericin (2) are two natural products, structurally belonging to the 
chemical class of naphthodianthrones (Figure 1) and the characteristic constituents of the genus 
Hypericum (Clusiaceae). Plants of this developed genus (comprising approximately 450 species) are 
widely distributed all around the world and have been used since antiquity for a range of medicinal 
properties. Hypericin and pseudohypericin were first isolated from Hypericum perforatum L., [1–3], 
which is the most important and commercially recognized representative of the genus. H. perforatum, 
commonly known as St. John’s Wort, is an aromatic, perennial herb growing up to 1 m high (Figure 
2). Its leaves are characterized by the presence of oil glands which may be seen upon holding the leaf 
to light, giving the impression of a perforated look, to which is attributed the name of the plant. The 
flowers, are bright yellow-orange, while the calyx and corolla are marked with numerous black 
glandular dots. When the black dots are rubbed between the fingers, the fingers become red [4,5].  
Figure 1. Structures of hypericin and pseudohypericin. 
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(1) Hypericin: R = CH3 
(2) Pseudohypericin: R = CH2OH 
Figure 2. Hypericum perforatum L.  
  
(From: http://luirig.altervista.org/photos/hypericum_perforatum.htm/. Flora italiana.) Int. J. Mol. Sci. 2010, 11                 
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In H. perforatum, the naphthodianthrone content ranges from 0.05 to 0.30% [6], but it can vary 
depending on the cultivar, altitude, light conditions, period of the year [7]. The plant also contains 
protohypericin, protopseudohypericin and cyclopseudohypericin. All these occur mainly in the 
flowering parts of the plant and especially located in the dark glands [8]. Protohypericin and 
protopseudohypericin are considered to be the biosynthetic precursors of hypericin and 
pseudohypericin, respectively, from which the latter derive on exposure to light [9]. Also 
pseudohypericin is likely to be transformed to cyclopseudohypericin [10]. Protohypericin, 
protopseudohypericin and cyclopseudohypericin are detected in lower concentrations and are included 
in the analytical term “total hypericins” or “total naphthodianthrones” [11]. In general, the content of 
pseudohyhypericin (0.03–0.34%) is higher from that of hypericin (0.03–0.09%) two to four times [12], 
depending on the variety.  
1.2. Other Sources of Hypericin and Pseudohypericin 
Hypericin and pseudohypericin are found in several Hypericum sp. A recent review by Bruni and 
Sacchetti [7] shed ample light on the morphological and chemical variations among different 
Hypericum sp. and varieties. Hitherto, only a small part of the genus has been studied, whereas 
approximately ¾ of Hypericum species have not been surveyed for their chemical content. A recent 
survey on 74 Hypericum taxa (approx. 20% of the entire genus) [13] from different continents showed 
that hypericins were detected only in species of the Sections Hypericum, Adenotras, Drosocarpium. 
Generally, it seems that their presence is restricted to phylogenetically advanced sections of the genus. 
Hypericin and pseudohypericin are absent or negligible in the primitive sections, whereas in some taxa 
(H.  hirsutum,  H.  empetrifolium) only hypericin can be found [14]. Infrageneric chemotaxonomic 
surveys, have revealed that some Hypericum species, such as H.  boissieri,  H.  barbatum,  H. 
rumeliacum may contain a 2–4 fold higher amount of hypericins than H.  perforatum. The latter, 
however, still remains as the sole sourse of Hyperici Herba. There many reasons for this: its wide 
geographical diffusion from temperate to tropical mountain regions, its adaptation to diverse 
environmental conditions, its cultivation and of course its diffused therapeutic use. 
1.3. Endophytic Fungi 
Besides  Hypericum sp., hypericin has also been found in fungi such as Dermocybe [15] or 
endophytic fungi which grow in diverse Hypericum sp. or in other plant species. The latter source 
represents a very interesting field in the discovery of alternative ways for the production of hypericin. 
It has been hypothesized that, especially in tropical environments, plant-microbe interactions may lead 
to horizontal gene transfers (HGT) or genetic recombinations, from the plant to its endophytic 
counterpart or vice versa, that subsquently, lead to “novel” endophytes capable of accumulating certain 
metabolites specific to the host plants themselves. Although only certain specific novel endophytes are 
capable of producing certain host-specific compounds and host-microbe coevolution procedures are 
still unknown, these methods may present a new perspective for the production of natural products and 
have several advantages such as low cost, the use of renewable resources and finally reproducible 
results by use of fermentation technologies. In this framework, the possible microbial mechanism of 
hypericin and emodin biosynthesis was studied in axenic submerged culture conditions in the Int. J. Mol. Sci. 2010, 11                 
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endophytic fungus Thielavia subthermophila, isolated from H. perforatum [16,17]. Results showed 
that neither emodin anthrone nor protohypericin could be detected at any stage of fermentation, 
irrespective of either spiking or illumination conditions. Furthermore, the Hyp-1 gene was absent in T. 
subthermophila, indicating that the biosynthetic pathway in the endophytic fungus might be different 
and/or governed by a different molecular mechanism than the host plant or host cell suspension 
cultures. 
2. Biosynthesis  
The biosynthesis of hypericin and pseudohypericin, is presumed to follow the polyketide   
pathway [1], according to which, in a first step one molecule of acetyl CoA condensates with seven 
molecules of malonyl CoA to form an octaketide chain that subsequently undergoes cyclizations and 
decarboxylation, leading to the formation of emodin anthrone (Figure 3).  
Figure 3. Biosynthesis of hypericin. Oxidation towards the pseudohypericin pathway is 
presumed to occur after the condensation reaction. 
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Emodin anthrone is considered to be the precursor of hypericin. As it has been suggested [8,18], 
emodin anthrone is oxidized to emodin, probably by the enzyme emodinanthrone-oxygenase and then 
through a condensation reaction yields a dianthrone. Successive oxidations lead to the formation of 
protohypericin, which upon irradiation with visible light yields hypericin. Oxidation of the methyl 
group of protohypericin is presumed to lead to protopseudohypercin, which is similarly transformed to 
pseudohypercin under visible light. This biosynthetic root is generally accepted today, even though 
further investigations that would prove it are necessary, and most importantly, the polyketide synthases 
that would play a crucial role have not yet been characterised. Very recently, however, two cDNAs 
encoding for polyketide synthases (PKSs), designated as HpPKS1 and HpPKS2, were isolated from H. 
perforatum [19]. The HpPKS1 expression was highest in flower buds and lowest in root tissues and 
was found to correlate with the concentrations of hyperforin and adhyperforin in H.  perforatum 
tissues, while the expression of HpPKS2 showed correlation with the concentrations of hypericins and 
pseudohypericins and was found to be high in flower buds and leaf margins and low in leaf interior 
parts, stems and roots.  
Further studies by Bais et al. [20] revealed the presence of an enzyme, Hyp-1, from darkgrown H. 
perforatum cell cultures, that specifically catalyzes the direct conversion of the anthraquinone emodin 
to hypericin in vitro. It is hypothesized that Hyp-1 catalyzes an initial condensation reaction between 
emodin and emodin anthrone followed by a dehydration to form emodin dianthrone. Emodin 
dianthrone may eventually undergo phenolic oxidation to protohypericin, either by photoactivation or 
by Hyp-1 itself. Kosuth, et al. [21] studied the expression of the Hyp-1 gene in different organs of H. 
perforatum seedlings in early stages of development. Surprisingly, the highest level of expression was 
found in roots. This fact indicates that the sites of biogenesis and accumulation of hypericin in the 
Hypericum plants are independent of the expression of the Hyp-1 gene.  
3. Properties 
Hypericin has been extensively studied for its physicochemical properties, little is known however, 
for pseudohypericin. Hypericin is not planar, as indicated by X-ray diffraction studies [22]. The side 
chains of the aromatic skeletons repel each other and prevent the molecule from acquiring a   
planar conformation.  
There are 16 theoretical tautomers of hypericin [23], but the more stable one is the   
7,14-dioxoisomer. In concentrated hypericin solutions, the 1,6-dioxo isomer converts slowly into the 
7,14-dioxoisomer. Dilution of the solution or addition of pyridine DMSO, or other polar compounds 
accelerates the reaction. The 1,6-dioxo-tautomer is stabilized in the solid phase and concentrated 
solutions by intermolecular hydrogen bonds. Salts of hypericin with alkali metals retain the structure 
of the 7,14-dioxo-tautomer both in solutions and crystalline state [24].  
Hypericin has the affinity for forming associates. It dissolves monomolecularly in common polar 
solvents up to concentrations of 10
−3 mol/L. Under certain conditions (i.e., in the presence of water), 
however, it forms homoassociates. The form of the homoassociates depends on the tautomeric state of 
hypericin. Hydrophobic contacts of the aromatic core are responsible for the 7,14-dioxo tautomer, 
whereas hydrogen bonding is responsible for the formation of the homoassociates of the 1,6-dioxo 
tautomer. These homoassociates influence considerably the absorption spectra of hypericin and this Int. J. Mol. Sci. 2010, 11                 
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should be considered in the case of HPLC-DAD analyses. For example, the homoassociates of the  
1,6-dioxo tautomer show high extinction coefficients and narrow absorption bands [24,25] than those 
of the 7,14-dioxo tautomer. Falk and Meyer [25] reported that the extinction coefficient of hypericin in 
water is one fourth of that in pure dimethylsulfoxide.  
Other factors that influence the absorption spectra of hypericin, are solvent, the pH, its 
ionization [26], its tautomeric and conformational state [27]. Transformation from one tautomer into 
another only occurs in solution. Dilution, rise in temperature, addition of pyridine and dimethyl-
sulfoxide disturb the hydrogen bonds by dissolving the hypericin molecules, and therefore enhance the 
dissociation of the homoassociates.  
The proximity of acidic and basic functional groups on hypericin allows the formation of several 
hydrogen bonds which play a crucial role in the molecular recognition and specificity of its 
interactions with molecular targets. X-ray data indicated that, deprotonated hypericin forms five short 
intramolecular hydrogen bonds which influence the tautomeric equilibria and determine its acido-basic 
properties. Hypericin tends to dissociate one proton in polar solvents to give birth to hypericin 
anion [28]. This, anion influences the photosensitive features of hypericin. Furthermore, it has been 
suggested that an intramolecular proton transfer takes place and that the reaction is coupled to 
intramolecular conformational changes (excited-state tautomerization) [29,30]. 
The naphthodianthrones are poorely soluble in water [31], with pseudohypericin being more soluble 
in polar solvents due to the presence of the extra hydroxymethyl unit. It has been suggested that 
procyanidins could be responsible for the solubilization of naphthodianthrones in aqueous 
solutions  [32] by forming complexes. Potassium salts which increase the solubility and the 
extractability from the plant have also been described [26]. Binding to human serum albumin helps 
hypericin to solubilize in aqueous physiological solutions, as it leads in the dissociation of the 
aggregates usually formed in the aqueous phase into the monomeric form of hypericin [33]. Standard 
solutions of naphthodianthrones in methanol:pyridine (99:1, v/v) have been proposed as a means to 
dilute completely naphthodianthrones. The improved solubility upon the addition of pyridine is 
explained by the formation of naphthodianhtrone-pyridine complexes. Solutions have to be kept in the 
dark [32] to avoid photodegradation. Pseudohypericin degradation however, is slightly accelerated by 
the addition of pyridine. 
4. Stability 
Both substances are labile, especially under light. They seem to be more stable in St. John’s Wort 
extracts up to 48 h [34] but the stability of H. perforatum extracts is of no interest in the present 
review. Maisenbacher [35] studied the photodegradation of hypericin in acetone using a day lamp for a 
duration of 40 h. The samples were monitored with NMR and the authors concluded that hypericin 
degraded to lipophilic derivatives. Wirz et  al. [36], studied the stability of standard solutions of 
hypericin and pseudohypericin. All solutions were stable at −20 °C in darkness over the investigated 
period of 140 days. Higher temperatures, light and the presence of pyridine accelerated the degradation 
of pseudohypericin, light exposure being the most aggressive factor. Hypericin showed higher 
stability, than pseudohypericin in light. The instability in the presence of light was more pronounced in 
the extract solution both for hypericin and pseudohypericin. Under all the other storage conditions, the Int. J. Mol. Sci. 2010, 11                 
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stability of pseudohypericin was better in the extract solutions than in the standard solutions. pH is 
another factor that causes degradation of the naphthodianthrones. Acidic conditions caused 
decomposition of hypericin and pseudohypericin in extracts of H. perforatum, both under light and 
dark conditions [37]. Similarly, alkaline conditions caused a rapid degradation of pseudohypericin in 
standard solution or in Hypericum extracts [38,39]. According to our experience [40], standard 
solutions of pure hypericin and pseudohypericin presented a loss of 20% after four days at room 
conditions (temperature and light). These results highlight the need to carry out all isolations and 
handling of the compounds as fast as possible. 
5. Extraction, Isolation and Synthesis of Hypericin and Pseudohypericin 
5.1. Extraction and Isolation 
Several extraction methods of naphthodianthrones from Hyperici herba have been described, 
including maceration, sonication, Soxhlet extraction, supercritical fluid extraction and pressurized 
liquid extraction. Due to the very low content of naphthodianthrones in H. perforatum the extraction 
processes are of high cost and require multiple cycles and fast handling of the material, since 
hypericins are labile substances. The European Pharmacopaeia uses THF for the extraction.  
The extraction methods that have been applied use hydroalcoholic mixtures in different ratios. 
There are many contradictions in the literature concerning the solvent selection. In general, lower 
percentage in water favors the extraction of hypericin compared to pseudohypericin. Ang et  al. 
combined methanol 100% with sonication to quantitatively extract the naphthodianthrones [37,41], 
while Draves et al. [42] reported the combination of ethanol 100% with sonication. The extraction was 
found to be rapid and to recover more than 95% of both pseudohypericin and hypericin following 1 h 
of sonication.  
Williams  et  al. compared different methods using a variety of solvent, temperature and time 
conditions [11]. In particular, they performed (i) sonication with methanol for 120 min at 60 °C, (ii) 
Soxhlet extractions over five time intervals at five different extraction times: 52 min, 140 min   
(six cycles), 8, 24, and 48 h. and (iii) pressurized liquid extraction using methanol, tetrahydrofuran, 
acetone, methylene chloride, and hexane at room temperature. PLEs were also carried out at several 
elevated temperatures, 60, 100, 150, and 200 °C, using methanol. They concluded that the highest 
levels of polar and nonpolar constituents were achieved through Soxhlet extraction of botanical 
samples over a 24 h period. In general, more complete extractions resulted with longer extraction times 
and multiple solvent contacts. Higher yields of polar constituents were achieved with tetrahydrofuran, 
whereas less polar constituents such as hypericin and pseudohypericin were more completely extracted 
with acetone. 
Similar results reported recently Smelcerovic et  al. [43], who compared direct sonication with 
conventional maceration, indirect sonication, Soxhlet extraction, and accelerated solvent extraction 
(ASE). Six active compounds were considered, among them hypericin and pseudohypericin. Direct 
sonication gave the best results. Conventional maceration gave the lowest amount of analyzed active 
compounds. Soxhlet extraction gave better results than ASE or indirect sonication. 
Another interesting study was reported by Benthin et al. [44]. They developed an extraction process 
of multiple steps and compared it with the method used in the German Drug Code (DAC). After a Int. J. Mol. Sci. 2010, 11                 
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preliminary removal of undesirable lipophilic constituents by one extraction cycle with CH2Cl2 at  
100 °C, dianthrons were extracted by three cycles of 5 min each with MeOH at temperatures ranging 
from 50 to 100 °C. Extraction cycles 2 and 3 afforded further hypericin, but with significantly 
decreasing yields. The yield of total dianthrons was significantly higher in the PLE than in the extracts 
obtained by the German Drug Code method. In the contrary, supercritical extraction is unsuitable, as it 
leads to the isolation of the unpolar hyperforins [45].  
Due to the very low content of hypericin and pseudohypericin in Hypericum sp. the isolation of the 
naphthodianthrones is a complicated procedure, including many different separation steps. In the past 
various methods of isolation have been developed which mainly consist of HPLC analyses on RP-C18 
columns [37,46]. In other cases isolation protocols include the application of successive column 
chromatographies over silica [47,48], polyamide [49] or Sephadex LH-20 [50,51] which render the 
whole procedure labour-intensive and time consuming and as a consequence very expensive. A very 
interesting work on different separation methods of hypericin and pseudohypericin from H. perforatum 
was published by Smelcerovic et al. 2002 [52]. Flash chromatography, high speed counter-current 
chromatography, XAD solid phase extraction and Sephadex LH-20 column chromatography were 
tested, with the latter being proved to be the most convenient method for the separation of this type of 
constituents. Separation by Sephadex LH-20 afforded a fraction containing 33.7% hypericin and 40% 
pseudohypericin. However, a final purification by preparative HPLC was also needed. An elaborated 
but complicated isolation scheme was described by Wirz [53]. In brief, the method consisted of an 
initial liquid liquid partition with the system hexane-toluene-H2O-EtOAc-HCOOH 
(75:225:135:120:15, v/v), the upper level was collected and evaporated, redissolved in methanol and 
stored at 8 °C. A precipitated was formed which was subjected to high-speed counter current 
chromatography (HSCCC) using the solvent system toluene - acetonitrile - water - ethanol absolute 
(3:4:3:2, v/v) to yield pure hypericin and pseudohypericin. The first step was repeated four times in 
order to obtain a sufficient amount of pure naphthodianthrones. 
Recently, Karioti et  al. [40], reported an isolation scheme which combined partition and size 
exclusion chromatography using different Sephadex gels. According to this method the H. perforatum 
dried methanolic extract was redissolved in aqueous methanol (20%) and extracted initially with 
hexane in order to remove unwanted lipids and chlorophylls which absorb in the same UV range as 
naphthodianthrones. After partition with Et2O and EtOAc, the extracts were combined and further 
purified by successive polar (MeOH 70%) and lipophilic (EtOAc:MeOH 70:30) Sephadex LH-20 to 
yield high purity naphthodianthrones. In a last step a Sephadex LH-60 was applied to separate 
hypericin from pseudohypericin. Among the advantages of this method were the simplicity and the use 
of open short columns (and therefore fast). Scaling up of the procedure to higher amounts up to 10 g or 
35 g was feasible and with reproducible results. 
5.2. Synthesis  
Hypericins’ syntheses could be divided into two groups: (i) synthesis of the original constituents 
with the lowest possible cost in order to provide higher amounts of these rare compounds and (ii) 
synthesis of derivatives, the so-called, second-generation agents, characterized by redshifted 
absorption spectra, excitable at wavelengths with enhanced penetration depth and improved Int. J. Mol. Sci. 2010, 11                 
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physicochemical properties, such as solubility, an enhanced ability to generate singlet oxygen and/or 
reactive oxygen species, bioavailability, or targeting of specific cellular sites.  
5.2.1. Synthesis of hypericin and pseudohypericin 
The chemical synthesis of hypericin follows the pattern of the proposed biogenesis. The first 
synthesis was achieved by Brockmann [54,55]. Later, Falk and coworkers proposed a semisynthetic 
route starting from the easily available anthraquinone precursor emodin [56] and, in parallel, they 
developed a convenient synthesis of emodin [57]. Recently, the same group proposed an improved 
method by employing microwave technology for the preparation of hypericin in higher yields [58]. 
With this methodology dimerization of identical ‘‘halves’’ (anthrones) leads to symmetrical 
derivatives, while, most importantly, by using or mixed ‘‘halves’’ (anthrone and quinone) via the 
corresponding protohypericin. The same method was applied with success for the preparation of 
hypericin derivatives ans most importantly it can be used for the production of unsymmetrical 
hypericin derivatives. Main advantages of the application of microwave assisted solid phase synthesis 
for the preparation hypericins, apart from the higher yield, are the absence of high boiling solvent and 
decreased reaction time. A six step synthesis of hypericin via emodin anthrone starting from the simple 
1,4-benzoquinone was reported by Motoyoshiya et al. [59].  
5.2.2. Synthesis of analogues with improved physicochemical properties, solubility and targeting of 
specific cellular sites 
A great variety of synthetic hypericin derivatives has been lately designed aiming to produce 
molecules with improved physicochemical properties, enhanced solubility, interaction with DNA, 
accumulation in particular tissues and finally acting as imaging agents. Some of the reports provide 
data on the efficacy of such products. A simple method to determine the phtochemical behaviour of the 
synthetized compound is to irradiate the hypericin derivatives in the presence of sodium bilirubinate 
IXa. With this method the photosensitized production of singlet oxygen and⁄or reactive oxygen species 
from molecular oxygen in aerated solutions is determined by monitoring the oxidative destruction of 
bilirubin IXa.  
Falk and co-workers, renowned for their research in hypericin synthesis and the elucidation of the 
physicochemical properties of this molecule, developed a new class of modified hypericin derivatives, 
which contained extra heterocyclic rings such as benzothiazolyl, benzoxazolyl [60] and 
benzothiazole  [61]. Basic concept of these syntheses was that the methyl groups of the hypericin 
moiety served as ‘‘anchors’’ for the substitution by the extra chromophore units. In this way, the 
photophysical properties of the hypericin chromophore remained more or less untouched. In parallel, 
the same team developed a group of amino functionalized hypericin derivatives [62] with excellent 
overall yields and enhanced solubility. 
The observation that nitrogen containing heterocyclically substituted derivatives presented a 
pronounced bathochromically shifted absorption spectra, led to the design of a new series of 
derivatives, where the hypericin chromophore was fused with nitrogen containing heterocyclic rings: 
phthalazines, phthalazinones and pyridazinones [63]. Generally, the improved photochemical Int. J. Mol. Sci. 2010, 11                 
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properties of these derivatives are attributed to the nature of the fused aromatic heterocycle which 
allows an efficient delocalization of the π-electrons of the phenanthroperylenequinone moiety.  
Hypericin derivatives containing dicyclohexylurea moieties have been also synthetized. They 
showed excellent production of oxidizing species comparable to hypericin. [64]. The authors however, 
do not mention how the insertion of the sulfur containing unit could modify the interaction with cell 
components. 
Hybridization products of hypericin with porphyrin have been described. The concept of this 
synthesis was to combine the intense long-wavelength absorption of hypericin with the very weakly 
absorbing, but highly tumor-targeting properties of porphyrins [65].  
In an attempt to create hypericin derivatives potentially interacting with the complementary nucleo-
bases of DNA or RNA by Watson-Crick pairing, or intercalation, or with other constituents of the cell 
nucleus, hybridization of hypericin with nucleobases was performed. Although no specific interaction 
with DNA or Watson-Crick base pairing with poly(20-deoxyadenylic acid) could be detected, the 
products accumulated in the nucleus of prostatic cancer cells better than hypericin. [66].  
Crnolatac et al. [67], synthesized a series of more lipophilic hypericins i.e., hexyl-, octyl-, decyl- 
and dodecylamides of hypericin acid. In  vitro cellular uptake and photo-induced antiproliferative 
effects of the compounds were evaluated, using the human moderately differentiated non-invasive 
papillary transitional carcinoma RT-112 cell line, whereas the more lipophilic amides were taken up 
limitedly, the hexylamide accumulated approximately as well as hypericin itself.  
The synthesis of radioiodine labeled hypericin was also reported as a malignant glioma imaging 
agent. [68]. In all glioma cell lines, 2-[123I]iodohypericin uptake was increased in a time dependent 
manner and an accumulation of 2-[124I]iodohypericin was observed in C6 glioma bearing nude 
mouse. The results suggested that radioiodine labeled hypericin could visualize a PKC overexpressed 
malignant glioma. In contrast, a 99mTc-labeled hypericin derivative did not show preferential uptake 
in necrotic tissue [69] and thus considered as not suitable for imaging necrosis.  
A second generation carbohydrate-linked hypericinic photosensitizing agent was synthetized with 
enhanced solubility [70]. Its photochemical properties resulted to be better than those of hypericin, 
while it showed binding-interactions with DNA. 
Finally, unusual cationic hypericin derivatives were synthetized and further assayed for their 
photobactericidal activity against Propionibacterium  acnes [71]. The quaternary N,N,N-trimethyl-
anilinium derivative of hypericin displayed a pronounced photodynamic inactivation of the bacteria at 
low incubation concentrations (<100 nM) and a short incubation time (1 h) after illumination. 
6. Photodynamic Therapy (PDT) and Cancer  
Hypericin has been extensively studied for its application in the photodynamic therapy. 
Photodynamic therapy (PDT) involves the administration of a tumor-localizing nontoxic drug known 
as photosensitizer, systemically, locally, or topically. The photosensitizer should accumulate in the 
tumor. After an incubation period follows illumination of the tissue or tumor with visible light (usually 
long wavelength red light) in the presence of oxygen, during which the photosensitizer (PS) is 
activated generating reactive oxygen species toxic to the tumor cells and thus leads to tumor death and 
tissue destruction.  Int. J. Mol. Sci. 2010, 11                 
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The use of PDT as a cancer therapy is particularly attractive because of its selectivity. This is better 
understood once the mechanism of PDT is considered. The photophysical processes that take place 
during PDT are very well explained in the review article by Castano et al. [72]. In brief, the PS 
absorbs light and is boosted from the ground state or singlet state (low energy at which the electrons 
occupy opposite spins) to the first excited singlet state. The excited singlet state PS may also undergo 
the process known as intersystem crossing whereby the spin of the excited electron inverts to form the 
so called excited triplet-state (electron spins parallel). The PS excited triplet can undergo two kinds of 
reactions (Figure 4): Type 1 reaction, during which it can react directly with a substrate, such as the 
cell membrane or a molecule, and Type 2 reaction, where the triplet PS can transfer its energy directly 
to molecular oxygen (itself a triplet in the ground state), to form excited state singlet oxygen. Both 
Type 1 and Type 2 reactions generate further reactions that have as a result the formation of ROS 
which are toxic to several cell structures and macromolecules (DNA, lipids, enzymes). Only molecules 
and structures that are proximal to the area of ROS production (areas of PS localization) are directly 
affected by PDT. Due to the fact that the PS localizes in the malignant tissue the light is also spatially 
focused on the tumor.  
Figure 4. Mechanism of photoactivation of hypericin and induced damages. 
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Three distinct (but possibly interrelated) mechanisms are involved in the observed shrinkage of 
tumors during PDT: (i) generated ROS kill tumor cells directly by apoptosis and/or necrosis;   
(ii) damages of the tumor-associated vasculature, lead to tissue deprivation of oxygen and nutrients 
and consequent tumor infarction and (iii) activation of immune responses against tumor cells [72,73]. 
Naphthodianthrones have a strong ability to generate singlet oxygen and other reactive oxygen 
species upon irradiation. Especially hypericin is one of the most powerful photosensitizers in nature. 
Vandenbogaerde  et  al. [74], studied comparatively the photocytotoxic effect of hypericin and 
pseudohypericin. Despite the structural resemblance pseudohypericin appears to be less effective than 
hypericin, probably due to decreased uptake of the former by the cells associated to irreversible 
interaction between pseudohypericin and serum constituents. Most importantly, this strong binding to Int. J. Mol. Sci. 2010, 11                 
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foetal calf serum resulted in decreased fluoroscence. The antitumoral activity of hypericin is oxygen 
dependent suggesting that both Type I and Type II mechanisms of photodynamic action are involved. 
[75,76]. It has been suggested that the Type II mechanism is the one to play a major role in the 
biological photoactivity of hypericin. However, newer evidence show that there may be an additional 
mechanism of photoactivation involving an intramolecular proton (or hydrogen) transfer, as discussed 
previously in Section 3.  
In the last years there is a continuously growing evidence of the effectiveness of hypericin in PDT. 
Most reports concern in  vitro studies on a variety of cell lines. Cells are firstly incubated with 
hypericin, irradiated and finally assessed by MTT assay for cell viability. Since this issue is analyzed 
extensively in previous review articles [77,78] in this report we will focus on newer data. In Table 1 
are summarized newer published reports. In all the investigations listed light activation was mandatory 
for the expression of the cytotoxic activity of hypericin. Of more interest are in vitro tests which gave 
positive results against childhood rhabdomyosarcoma and pediatric epithelial liver tumors.  
Table 1. In vitro studies using Hypericin - PDT in different cancer cell lines. 
Cell culture    Light    Reference 
      
human umbilical endothelial 
cells and human glioma cancer 
cells U-87 MG & U-373 MG 
+  sensitive only to photoactivated hypericin  [153] 
human HepG2 cancer cells   +    [154] 
hepatic hepatoblastoma HUH6, 
& HepT1 cells 
+  severe alterations only after illumination  [155] 
pediatric hepatocellular 
carcinoma HepG2 cells 
+  severe alterations only after illumination  [155] 
human lung SpcA1 cancer cells  +  light emitting diode as light source for 
photoactivation 
[156] 
human lung cancer cells A549  +    [157] 
MDA231 human mammary 
carcinoma cells 
+  light emitting diode as light source for PDT  [158] 
human renal carcinoma cells   +    [159] 
rhabdomyosarcoma cells and 
fibroblasts 
+  nearly complete inhibition of cell 
proliferation only after photoactivation 
[160] 
 
The phototoxic effect of UVA (400–315 nm)-activated hypericin in human pigmented versus 
unpigmented melanomas was also studied with in vitro assays [79]. It was reported that 3 μM of 
activated hypericin induced a necrotic mode of cell death in pigmented melanoma cells and 
melanocytes and an apoptotic mode of cell death in non-pigmented melanoma cells and keratinocytes. 
This difference in cell death in pigmented melanoma cells and melanocytes was attributed to the 
presence of melanin-containing melanosomes which under the strong oxidative effect of reactive 
oxygen species released toxic melanin precursors (of an indolic and phenolic nature) which led to cell Int. J. Mol. Sci. 2010, 11                 
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death. In contrast, non-pigmented melanoma cells and keratinocytes died by apoptosis related to a 
mitochondrial caspase-dependent mechanism. The same authors reported however [80], that exposure 
to hypericin induced initially a cytoprotective (autophagic) response from both cell lines, but in the 
end the cells succumbed with different susceptibilities to the hypericin induced stress. In addition, 
pigmented cells accumulated a large amount of glycogen in their cytoplasm which might be associated 
with inhibition of GSK3, which in case of melanoma has been linked to different modes of cell death. 
Some interesting findings concern the combination of hypericin with other agents in order to 
maximize its efficiency. A high sensitivity combination scheme can be also exploited in conventional 
cytological diagnosis or even in ex vivo fluorescence cytology [81]. Schneider-Yin et al. [82], reported 
that treatment of endometrial cancer cells with both aminolevulinic acid and hypericin followed by 
irradiation with white light induced a significantly higher phototoxicity. In another study, during 
which colon cancer cells HT-29 were pre-treated with the specific 5-lipoxygenase inhibitor MK-886, it 
was evidenced that cancer cells became more susceptible to photodynamic therapy (PDT) with 
hypericin and the combination induced cell cycle arrest and stimulated onset of apoptosis [83]. It was 
further presumed that pre-treatment with MK-886 modulated distribution of ROS production in mutual 
combination with PDT [84] and that apoptosis was accomplished preferentially through the 
mitochondrial pathway although caspase-8 activation was also noticed. However, recent findings show 
that high levels of arachidonic acid, a cyclooxygenase-2 and 5-lipoxygenase substrate, could act as 
death messenger and further induce apoptotic signals (For more details see Section 6.1). 
6.1. Mechanisms Linked to Apoptotic/Necrotic or Cell Survival Processes 
Many efforts have been made in order to comprehend the cellular processes implicated in hypericin 
PDT. The subcellular localization of hypericin, the type of the tissue/cell and the light dose are some 
of the factors that influence the fate of the cancer cells: necrosis, apoptosis, or survival. Different 
cellular mechanisms are activated in each case, but most of the times co-evolve in different proportions 
and interrelate [85] (Figure 5). The photocytotoxic pathways that have been identified include 
inhibition of protein kinases (C, A), protein tyrosine kinases and other growth factor-stimulated protein 
kinases [77], membrane lipid peroxidation [86], downregulation of matrix metalloproteinase-1 [87], 
increase of superoxide dismutase activity, decrease of cellular glutathione level [88]. Mitochondrial 
apoptotic pathways are also responsible, such as inhibition of mitochondria outer membrane bound 
hexokinase, or activation of the caspase signalling system and release of cytochrome c into the cytosol. 
Mitochondrial damage has been identified as one of the main events during PDT with hypericin [89]. 
In contrast, soon after irradiation, JNK1 and MAPK (Mitogen-Activated Protein Kinase) pathways are 
activated independently of the caspace activation leading to an increased cellular resistance against 
hypericin induced apoptosis [78]. Other cellular mechanisms that may contribute to cell resistance 
during PDT with hypericin include intracellular redox enzymatic systems with free radical scavenging 
capabilities such as the glutathione S-transferase, glutathione reductase and others. 
Necrosis was found to be the principal procedure of cell death in colon adenocarcinoma HT-29 cells 
[90]. This occurred irrespectively of different PDT doses and the absence of anti-apoptotic Bcl-2 
expression. Introduction of Bcl-2 into HT-29 cells caused caspase-3 activation, changed the Bcl-XL 
expression pattern, increased the apoptosis ratio with no effect on overall toxicity, and supported arrest Int. J. Mol. Sci. 2010, 11                 
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in the G2/M-phase of cell cycle. Since it is known that Bcl-2 suppression in HT-29 is reversible and 
linked to the over-expression of mutated p53 and also considering our data, we suggest that the 
mutation in p53 and events linked to this feature may play a role in cell death signalling in HT-29 
colon cancer cells. 
Similarly, in an in vitro study on human epidermoid carcinoma cells (A431) [91], a transition from 
apoptosis to necrotic cell death was observed at higher light doses. Intermediate ligh doses of   
1.44 J/cm
2 induced apoptosis. Time resolved analysis of the apoptotic processes showed a significant 
activation of caspase-2, -3, -6, and -9, and most importantly, rapid reduction of the mitochondrial 
membrane potential which clearly proved mitochondrial involvement in the apoptotic process. 
Analysis of the energetic characteristics of hypericin-PDT induced apoptosis revealed that the levels of 
intracellular ATP remained at control level for up to 6 h post irradiation. This fact suggested that the 
energetic supply for the ATP dependent steps during apoptotic cell death is independent of 
mitochondrial ATP synthesis. Upregulation of glycolysis may have served as a compensating 
mechanism of energy supply. 
Figure 5. Some of the multiple and interrelating signaling pathways induced during PDT 
with hypericin. 
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(1)  high dose of light leads to necrosis.  
(2)  medium light doses activate different apoptotic pathways: (2a) activation of caspase -8 and 
final activation of the caspases -3, -6, -7; (2b) mitochondrial release of cytochrome C, Int. J. Mol. Sci. 2010, 11                 
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accompanied by mitochondrial Ca
2+ release leads to activation of the caspases -3, -6, -7 via 
activation of caspace -9. Bax/Bid proapoptotic proteins enhance the cytochrome C release, 
whereas the antiapoprotic Bcl-2 inhibits the cytochrome C reflux; (2c) Ca
2+ release from the 
endoplasmic reticulum activates cytochrome C release from mitochondria. 
(3)  inhibition of the ERKs induces cytostatic responces. 
(4)  low light doses favor the MAPKs pathway leading to cell survival: activation of MAPKs 
JNK1 and p38α pathways leads to cell survival and angiogenesis. 
Apoptosis events seem also to be related with a raise of the intracellular Ca
2+ levels which occurs 
via influx of Ca
2+ through ion channels, release of Ca
2+  from the endoplasmic reticulum or 
mitochondria or ion exchange mechanisms [85]. In an in vitro study on human prostate carcinoma cells 
mitochondrial aconitase, an enzyme exquisitely sensitive to oxidation, revealed a dose correlated loss 
of activity immediately after hypericin photoactivation, suggesting mitochondrial impairment. 
Combination with ionomycin, which modulates both internal Ca
2+ stores and external Ca
2+ transport, 
profoundly enhanced photocytotoxicity [92]. 
In an in vitro analysis of the local and temporal changes of the Ca
2+ concentration after hypericin-
PDT in human U373 glioblastoma cells [92] it was shown that low light doses (under 1 J/cm
2) induced 
Ca
2+ oscillations, which might be explained as Ca
2+ transport between mitochondria and endoplasmic 
reticulum. On the contrary, at higher light doses (over 3 J/cm
2), Ca
2+ overload and subsequent Ca
2+ 
release into the cytoplasm were observed. Furthermore, after incubation of cells with hypericin and the 
mitochondrial marker MitoTracker green, a colocalization of the two dyes was observed in 
mitochondria, suggesting that these cellular organelles consist a major target of the hypericin 
phototoxicity. Authors proposed that the damage of mitochondrial ion pumps caused by reactive 
oxygen species could be responsible for the temporal changes in the cytosolic Ca
2+ concentrations 
observed. 
The role of endoplasmic reticulum in the intrinsic apoptosis and its relation to the Ca
2+ homeostasis 
was the subject of another study by Buytaert, et al. [94]. In general, the antiapoptotic Bcl-2 protein 
protects cells from stress-induced apoptosis by reducing the resting endoplasmic reticulum Ca
2+, 
whereas proapoptotic Bax and Bak proteins are required to maintain endoplasmic reticulum Ca
2+ pool 
necessary for the induction of apoptosis by Ca
2+ mobilizing stress signals [95]. Buytaert, et  al. 
proposed that during PDT with hypericin occurs loss of the native SERCA2 protein levels and 
consequent endoplasmic reticulum Ca
2+ depletion which causes disruption of Ca
2+ homeostasis and 
cell death. Apoptosis was rapidly initiated after endoplasmic reticulum Ca
2+ depletion, while the 
multidomain Bax/Bak proteins are strictly required for fast effector caspase activation and induction of 
intrinsic apoptosis. It was also observed that in the absence of Bax and Bak proteins (Bax−/−Bak−/− 
double-knockout cells), cells are protected from apoptosis but undergo autophagy-associated cell death 
[96]. It was concluded that after endoplasmic reticulum photodamage and disruption of Ca
2+ 
homeostasis, Bax and Bak proteins model PDT-mediated cell killing, which is executed through 
apoptosis in their presence or via an autophagic pathway in their absence. 
Dua et al. [97] reported the down-regulation of matrix metalloproteinase-9 following hypericin-
PDT in well-differentiated human nasopharyngeal cancer cells infected by the Epstein Barr virus. 
Epstein Barr is strongly related to the promotion of nasopharyngeal cancer and also with the 
expression of MMP-9. The authors initially confirmed the presence in the HK1 NPC genome of the Int. J. Mol. Sci. 2010, 11                 
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Epstein Barr virus encoded RNA 1 (EBER1) transcript. It was postulated that the observed down-
regulation of matrix metalloproteinase-9 was due to inhibition of granulocytemacrophage colony-
stimulating factor (GM-CSF) production which resulted in decreased binding activity of NF-kB and 
AP-1 transcription factors.  
MAPKs are found in all eukaryotic organisms and although they can regulate cytoplasmic targets, 
their ultimate role is to transmit extracellular signals to the nucleus where the transcription of specific 
genes is induced by phosphorylation and activation of transcription factors. Three distinct MAPK 
pathways have been characterized in mammalian cells: the extracellular signal-regulated kinase (ERK) 
cascade, the c-Jun N-terminal kinase (JNK; also called the stress-activated protein kinase, SAPK) 
cascade, and the p38 MAP kinase cascade [98].  
The role of PDT activated MAPKs in cell death regulation has not been fully elucidated. The ERK 
pathway (ERK1⁄2) is associated with cell survival, is activated by growth factors and induces cell 
proliferation [99,100]. The JNK and p38 MAPK activation cascades are activated mainly in response 
to a variety of extracellular and intracellular stress-stimuli such as oxidative stress, inflammatory 
cytokines and UV insult which is related to the activation of the cell death signalling 
pathways  [101,102]. Four isoforms of MAPK superfamily, p38-α, -β, -γ and -δ, exist, commonly 
activated by cellular stress, proinflammatory cytokines and growth factors [103].  
Based in newer scientific evidence, hypericin-PDT activates rescuing responses, chiefly governed 
by the activation of P38 MAPK: JNK1 and p38 MAPK are activated, while ERK2 is irreversibly 
inhibited [104,105]. This activation is independent of the caspase activation cascade and functionally 
signals to a survival response during PDT with hypericin, without however, rescuing cells from death. 
Most likely they delay the apoptotic process by inducing the transcription of survival-promoting 
genes [106] until a critical threshold of damage finally commits the cells to apoptosis [104].  
Chan and coworkers [107] have investigated the role of MAPKs in HY-PDT-induced apoptosis of 
nasopharyngeal HK-1 NPC cancer cells using both chemical inhibitors and small interfering RNA 
(siRNA). Results showed that mitochondrial (Bax) translocation and formation of Bax channel, as well 
as proteolytic cleavage of procaspase-9 and -3 in HK-1 cells took place. The observed increase in 
phosphorylation of p38 MAPKs and c-Jun N-terminal kinase 1/2 (JNK1/2) was inhibited by the use of 
the singlet oxygen scavenger L-histidine, showing that MAPKs pathways are activated via the 
induction of oxidative stress in HK-1 cells, whereas blocking the expression p38a MAPK (p38a) and 
p38b MAPK (p38b) isoforms of the MAPKs enhanced the HY-PDT-induced apoptosis of HK-1.  
Buytaert and coworkers [108] studied the gene expression following hypericin PDT in bladder 
cancer cells. Results demonstrated that PDT strongly affects various metabolic processes, stress-
induced cell death, autophagy, proliferation, inflammation and carcinogenesis. Analysis of   
PDT-treated cells after p38-MAPK inhibition or silencing unraveled that the induction of an important 
subset of differentially expressed genes regulating growth and invasion, as well as adaptive 
mechanisms against oxidative stress, is governed by this stress-activated kinase. Moreover,   
p38-MAPK inhibition blocked autonomous regrowth and migration of cancer cells escaping   
PDT-induced cell death. Authors concluded that hypericin-PDT pinpoints a coordinated induction of a 
cluster of genes involved in the unfolded protein response pathway after endoplasmic reticulum stress 
and in antioxidant response. This analysis identifies new molecular effectors of the cancer cell Int. J. Mol. Sci. 2010, 11                 
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response to PDT opening attractive avenues to improve the therapeutic efficacy of hypericin-based 
PDT of bladder cancer. 
From a recent study, activation of p38a MAPK appears to be crucial for the induction of 
cycloxygenase-2 (COX-2) expression and PGE2 synthesis in the hypericin PDT-treated cells [109]. 
This finding is very important, since the p38a MAPK mediated COX-2 expression may facilitate the 
growth of cells endowed with resistance to PDT and with the potential to progress to malignancy. It 
has been evidenced that hypericin PDT leads to a rapid rise in the levels of cytosolic calcium which 
generates the accumulation of arachidonic acid via phospholipase A2 activation (PLA2) (Figure 5). 
Arachidonic acid seems to act as a death messenger for the cell and its depletion by overexpressed 
cyclooxygenase-2 leads to further synthesis of prostaglandin PGE2 and upregulation of vascular 
endothelial growth factors (VEGF), which in turn favors tumor neoangiogenesis, thereby supporting 
local tumor progression and metastatic spreading. Hendrickx and coworkers [109] demostrated that 
inhibition of p38α MAPK blocked the release of vascular endothelial growth factor and suppressed 
tumor-promoted endothelial cell migration. Hence, targeted inhibition of p38α MAPK could be 
therapeutically beneficial to PDT, since it would prevent COX-2 expression, the inducible release of 
growth and angiogenic factors by the cancer cells, and cause an increase in the levels of free 
arachidonic acid which promotes apoptosis. 
Hence, the specific targeting of p38a MAPK surpasses the effect of COX-2 enzymatic inhibition as 
it possibly targets additional mediators of the survival and angiogenic switch in cancer cells. In fact, 
emerging evidence indicates that besides regulating COX-2 expression, the activationof p38 MAPK 
can critically contribute to the process of carcinogenesis by regulating the turnover of labile metastatic 
gene transcripts, including matrix metalloproteinases and urokinase-type plasminogen activator, as 
well as by up-regulating genes involved in the adaptive response to oxidative stress. In addition, it is 
possible that the p38MAPK pathway regulates the activity of other AA-metabolizing enzymes besides 
COX-2, such as 5-lipoxygenase, as the simultaneous inhibition of these AA-converting enzymes is 
required to increase the susceptibility of the T24 cells to PDT-induced cell death. Since eicosanoids 
produced by the activation of lipoxygenases have been reported to stimulate VEGF synthesis, this 
could also explain why blockage of p38 MAPK is more effective in suppressing the VEGF release 
than the unique inhibition of COX-2. Moreover, recent studies have indicated that some COX-2 
growth-promoting functions are independent of the COX-2 enzymatic activity. Hence, the inhibition of 
p38 MAPK, resulting in the shut down of COX-2 expression, appears more promising as new 
treatment strategy in our paradigm than the use of COX-2 inhibitors, since it may encompass all  
COX-2-dependent phenotypes, including those merely mediated by its elevated expression. 
Taken together, these results encourage further in vivo studies to assess the potential antiangiogenic 
and pro-apoptotic role of the combined pharmacological inhibition of p38 MAPK in hypericin-based 
PDT of tumors. 
6.2. Modulation by Redox Cellular Systems 
The hypericin-mediated photodynamic effects are often modulated by cellular antioxidant defense 
mechanisms. Under extreme stress conditions cells activate their antioxidant defense mechanisms 
against reactive oxygen species in order to cope with the initial radicals produced, but also the Int. J. Mol. Sci. 2010, 11                 
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resultant and potentially more toxic products of the catalyzed and spontaneous reduction reactions. 
Among these enzymes that have been credited with this role and are frequently over-expressed in 
tumors are the group of glutathione reductases, glutathione peroxidases, the cytosolic glutathione   
S-transferases (GSTs) and the metallothioneins [110–112] Common feature of the above enzymatic 
systems is the presence of cysteine units which render them potent free radical scavengers and function 
as effective detoxification system that play a pivotal role in the protection of cells against damage 
induced by free radicals [113,114]. It has been hypothesized that co administration of a substance 
blocking such redox systems could enhance the efficacy of hypericin PDT [115,116]. Furthermore, this 
cell response to oxidative stress is also related to the irradiation conditions. For example, regeneration 
of reduced glutathione (GSH) during dark intervals was considered to be responsible for the resistance 
of cells to PDT in an in vitro study with fractionated irradiation (light/dark intervals of 45/60 sec) 
[117] using A431 human epidermoid carcinoma cells.  
In a recent in vitro study by Karioti et al. [118], hypericin and in a higher extent pseudohypericin 
inhibited in the dark thioredoxin reductase I and II. Interestingly, the polar pseudohypericin binded 
stronger than hypericin to the enzyme causing inhibition comparable to cisplatin. Dabrowski et 
al. [119], using human kidney 293 cells observed that increased glutathione S-transferases expression 
is inversely correlated with hypericin efficacy in PDT. Surprisingly, GSTP1-1 over-expression led to 
an increase in cellular uptake of hypericin, which suggested that this may result from direct 
sequestration of hypericn by GSTP1-1. It was also postulated that over-expression of GSTP1-1 caused 
a change in the expression of transport proteins, and thus altered the steady-state levels of intracellular 
hypericin. Alternatively, the oxidative stress caused by PDT may have led to higher levels of lipid 
peroxidation products and GSH conjugates. These, in turn, could compete with hypericin for 
transporter sites, thus leading to an increased intracellular concentration of hypericin. Finally, it was 
suggested that that cells overexpressing GSTP1-1 could protect neighboring cells from hypericin-
dependent PDT by sequestering the photosensitizer. 
In contrast, in another study depletion of intracellular glutathione reductase (>85%) in human 
prostate carcinoma cells via inhibition of γ-glutamyl-cysteine synthase had no effect on hypericin 
phototoxicity [120], thus precluding any direct oxidative involvement of H2O2. Also, there was no 
change in intracellular SOD activity immediately after hypericin irradiation.  
In another in vitro study [121] in well-differentiated HK1 nasopharyngeal cancer cells a differential 
up-regulation of metallothionein in isoforms was observed: MT-1E and MT-2A isoform were up-
regulated of six hours following PDT, with an approximately 50-fold rise in the expression level of 
MT-1E and a 15-fold increase of MT-2A. However, cells still succumbed to PDT-induced necrosis. It 
appears that the oxidative stress induced by PDT overwhelmed the antioxidant defense mechanism 
such as the alteration of MT levels in tumor cells. 
6.3. Anti-angiogenic Antimetastatic Activity  
As mentioned initially, PDT causes serious damages to the tumor vascular endothelial cells 
resulting to microvascular collapse. In molecular level, inhibition of the phosphorylation and 
activation of the ERK pathway has been reported [122]. Nevertheless, microvascular collapse may Int. J. Mol. Sci. 2010, 11                 
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lead to a better tumor control, on one hand, but on the other hand, tumor hypoxia, upregulates several 
pro-angiogenic factors. 
Bhuvaneswari et al. studied the angiogenic responses in a human bladder carcinoma xenograft 
model under short (0.5 h) and long (6 h) drug light intervals of hypericin-PDT treatment at 24 h and  
30 days post treatment [123]. Short drug light interval PDT caused extensive vascular damage. In the 
contrary, long drug light interval hypericin-PDT induced the expression of angiogenic proteins, such 
as vascular endothelial growth factor (VEGF), tumor necrosis growth factor-α (TNF-α), interferon-α 
(IFN-α) and basic fibroblast growth factor (bFGF). Similarly, using another model (in vivo human 
nasopharyngeal xenograft model) the same group [124], made similar observations: VEGF levels were 
found to be higher when the tumors were treated at a 1 h drug-light interval compared to a 6 h interval, 
due to extensive vascular damage, whereas 72 h after hypericin-PDT, VEGF levels were upregulated 
indicating the initiation of regrowth in tumors. With the co-administration of the angiogenesis 
inhibitor, celebrex®, a downregulation of the human VEGF levels was observed, suggesting an 
alternative way to overcome the angiogenic post hypericin PDT effect and improve the outcome of 
hypericin-PDT in nasopharyngeal carcinomas. Neverthelless, the time of the initial administration of 
Cerebrex-post PDT is also an important factor for the tumor control [125]. 
The anti-angiogenic effects of hypericin seem to be irrelevant to the presence or not of light. In an 
in vitro study by Martinez-Poveda et al. [126], the effects of non-photoactivated hypericin in key steps 
of angiogenesis, (including proliferation, tubular formation, extracellular matrix protease production, 
migration and invasion) were studied on bovine vascular endothelial cells. Hypericin in the dark 
inhibited moderately endothelial cell proliferation with an IC50 of 10 μM (vs. 13 nM of photoactivated 
hypericin). Most notably, it inhibited the formation of tubular-like structures on Matrigel in the same 
range of concentration as the photoactivated hypericin and in lower or in the same range of 
concentrations of other known inhibitors. Hypericin also presented inhibitory effects on migration and 
invasion of endothelial cells by causing a remarkale decrease in the levels of extracellular matrix 
degrading urokinase but not on those of matrix metalloproteinases MMP-2. In  vivo studies also 
confirm the antimetastatic activity of hypericin in the dark [127]. Treatment with hypericin 
significantly reduced growth rate of metastases in two murine models: breast adenocarcinoma (DA3) 
and squamous cell carcinoma (SQ2). Hypericin was reported to accumulate in primary and metastatic 
tumors and its content in lungs bearing metastases was measured to be approximately 2-fold higher 
than in the lungs of healthy animals. Long-term animal survival in DA3 tumor-excised groups 
increased from 15.6% in controls to 34.5% following supplementary treatment with hypericin, whereas 
in mice bearing SQ2 tumor metastases, therapy with hypericin increased animal survival from 17.7% 
in controls to 46.1%. 
7. Antidepressive Effects of Naphthodianthrones  
Currently, from all the scientific literature it is generally accepted that St. John’s wort preparations 
have a good profile of efficacy in mild to moderate depression and high tolerability. For this reason 
literature data concerning the antidepressive activity of isolated naphthodianthrones are limited.  Int. J. Mol. Sci. 2010, 11                 
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Early biochemical studies reported that hypericin is an inhibitor of MAO-A and MAO-B activity 
[128]. The concentrations that produce 50% inhibition (IC50) ascertained by Suzuki [128] are 100- to 
1,000-fold higher than accessible Cmax values of hypericins after oral administration of SJW extracts.  
Hypericin can bind to the GABAA receptors and at the 5-HT1 receptor [129], while has no 
significant affinity (<10% inhibition) for the following receptors: adenosine (A1 or A2), adrenergic (α1, 
α2 or β1), angiotensin (AT1), central BZD, cloned human bradykinin (B2), D1, GABA, cloned human 
tachykinin NK1, NPY, opioid, PCP, glucocorticoid, or vasopressin (V1). It has weak affinity (10–40% 
inhibition) for CCKA, D2, cloned human endothelin ET A, NMDA, central H1 and central nAChR sites. 
The two highest levels of inhibition (>40%) are at (non selective) muscarinic cholinergic receptors 
(49%) and at (non selective) σ receptors (about 48%) [130]. The affinity for NMDA receptor has also 
been confirmed by another investigation [131]. Hypericin and pseudohypericin inhibit the binding to 
rat D3 and D4 receptors, hypericin, but not pseudohypericin, inhibits binding to rat β1- and rat   
β2-adrenoceptors. Neither substance affects the SERT, the 5-HT receptor or the NA transporter [132]. 
Surprisingly, a 5-HT concentration increase was observed in the hypothalamus of rats after 
administration of pure hypericin for eight weeks, but not for two weeks administration. In contrast, the 
concentration of NA was reduced in the hippocampus after two weeks of daily administration of 
hypericin, whereas in the hypothalamus hypericin had no effect on NA levels. Nevertheless, hypericin 
showed efficacy in the Porsolt test, a sensitive depression animal model [32]. 
Hypericin inhibits the enzyme dopamine-β-hydroxylase with an IC50 of 3.8 μmol/L [133,130], 
whereas tyrosinase and tyrosine decarboxylase are not influenced by 1 to 10 μM hypericin [134]. 
Pseudohypericin also inhibits the enzyme dopamine-β-hydroxylase (IC50 = 3 μM) [130].  
Hypericin increased 5-HT concentrations in the hypothalamus after chronic treatment for 8 weeks 
and exhibited neuroendocrine effects in rats by decreasing plasma levels of adrenocorticotropic 
hormone and corticosterone after 14 days of oral treatment [132,135]. It also affected the transcription 
of genes involved in the regulation of the hypothalamic–pituitary–adrenal axis: mRNA levels of both 
corticotropin-releasing factor (CRF) and serotonin 5-HT1A receptor were decreased in the 
hypothalamic paraventricular nucleus and in the hippocampus, respectively [136]. Since corticotropin-
releasing factor (CRF) seems to be a major determinant in the regulation of the hypothalamic–
pituitary–adrenal activity via activation of CRF1 receptors, hypericin and pseudohypericin were 
assayed for their antagonist activity on the CRF1 receptor. Pseudohypericin selectively antagonised 
CRF (KB 0.76 AM) and the authors concluded that pseudohypericin is the only real CRF1 receptor 
antagonist [137]. 
8. Antiviral Activity 
Hypericin and in lesser extent pseudohypericin have been the subject of intense research for their 
antiviral properties. A detailed review article by Kubin et al. [77] has covered this topic. In general, 
hypericin has exerted antiviral activity in vitro against a great variety of viruses.It has shown virucidal 
activity by inhibiting viral infectivity in a hypericin-preincubation and light-dependent inactivation 
reaction and/or (II) antiviral activity by inhibiting viral replication in cell cultures. This activity is 
influenced a great deal by the presence of light and oxygen. Both factors seem to be important for the 
antiviral/virucidal properties of the molecule. Int. J. Mol. Sci. 2010, 11                 
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Further studies in recent years have shown that hypericin inhibited human cytomegalovirus in 
vitro [138], inhibited the adsorptive ability of Foot-and-Mouth virus (FMDV) to host cells in vitro on a 
model of BHK-21 cells with maximal inhibitory rate of 59.72% [139] and had a dose-dependent 
activity against porcine reproductive and respiratory syndrome virus (PRRSV) in amodel of Marc-145 
cells [140]. The maximum of activity was observed (cell survival rate and inhibitory rate) when the 
Marc-145 cells were pretreated with hypericin and then challenged with the viruses. The authors do 
not comment on the light conditions. In another study [141] on HHV-6-infected lymphoblasts, 
hypericin was found completely inactive; again the light conditions are not described. Some 
interaction studies of hypericin with the with the human immunodeficiency virus-1 reverse 
transcriptase [142] and HIV-1 protease [143] have been reported. However, as already highlighted by 
the review of Kubin [77], administration of hypericin on HIV-1 and hepatitis C virus patients gave 
dissapointing results, since no antiviral effect was observed, and instead, in the dosage used, patients 
showed phototoxicity. This contradiction between in vitro an in vivo studies could be explained in 
terms of light irradiation. The absence of light in many regions of the body limits the use of hypericin 
as a therapeutic compound for the treatment of viral infections in vivo.  
9. Antimicrobial Activity 
The traditional use of St John’s Wort includes the treatment for bacterial infections, respiratory 
conditions, skin wounds, peptic ulcers and inflammation [144]. Several antimicrobial assays have been 
carried out with extracts of different Hypericum sp. [145,146]. Unfortunately, data concerning the 
activity of isolated components are scarce and even more, there are no data concerning the influence of 
light or oxygen on the activity of hyperin or pseudohypericin. During an antibacterial evaluation of H. 
triquetrifolium Turra  [147],  bioguided fractionation led to the identification of quercetin and   
13,118-biapigenin as the substances responsible for the week antibacterial effect. Recently, on the 
other hand, hypericin and emodin isolated from an endophytic fungus of H. perforatum were assayed 
on a panel of laboratory standard pathogenic control strains, including fungi and bacteria. Both 
hypericin and emodin possessed antimicrobial activity comparable to authentic standards [17]. 
Furthermore, as already mentioned above, synthetic cationic derivatives of hypericin showed after 
irradiation strong antibacterial activity against the strain Propionibacterium acnes. 
10. Other Activities 
10.1. Ophthalmologic Applications 
The antiangiogenic effects of hypericin have been investigated for their possible exploitation in 
ophthalmologic applications and in particular retinopathy. In an in vitro study [148] of a mouse model 
of oxygen-induced retinopathy, administration of hypericin inhibited retinal neovascularization, but 
did not affect the area of retinal vasoobliteration. Most importantly, experiments were carried out in 
room conditions, and therefore without photoactivation of hypericin. Further in vivo studies [122] 
using rat eyes in several ocular models, demonstrated a strong angiogenetic inhibitory activity   
of hypericin.  Int. J. Mol. Sci. 2010, 11                 
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At molecular level, hypericin inhibited the activating phosphorylation of extracellular signal-
regulated MAP kinases (ERK1/2) in human retinal pigment epithelial cells and in EA.hy926 cells, an 
endothelial hybridoma expressing endothelial cell properties. MT1-MMP activity in human 
microvascular endothelial cells was also inhibited. All in vitro and in vivo experiments were performed 
in the dark, without light activation. Concerning the in vivo tests, however, one has to consider that the 
retina is accessible to light and therefore it is possible that light may have contributed to the high anti-
angiogenic activity potency of hypericin. This does not rule out the possibility that hypericin exerts 
antiangiogenic effects also in the dark, as discussed previously (see Section 6.2). 
10.2. Anti-inflammatory 
Light-activated pseudohypericin has been reported to inhibit the production of prostaglandin E2 
(PGE2) [149], while hypericin has been reported to reduce of Croton-oil-induced ear oedema in mice 
in concentration (ID50 0.25 μmol/cm
2) comparable to that of indometacin (ID50 0.26 μmol/cm
2) [150]. 
10.3. Interaction with b-Amyloid Peptides  
In an in vitro study by Sgarbossa et al. [151] hypericin at a concentration 10
−5 M prevented or 
arrested the aggregation process of 1–40 b-amyloid peptides. Hypericin was reported to interact also 
with the early precursors of the b-sheet fibrils and/or protofibrils. More interestingly, hypericin was 
used to monitor (in vitro) the appearance of early aggregation states of b-amyloid peptides during the 
polymerization process.  
On the contrary, in an in  vitro study using mouse microglial cell lines, neither hypericin nor 
pseudohypericin were able to protect microglia against amyloid beta [Aβ (25–35) and Aβ(1–40)] 
induced cell death [152].  
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